MX364310B - Método para preparar una formulación inmunosupresora. - Google Patents

Método para preparar una formulación inmunosupresora.

Info

Publication number
MX364310B
MX364310B MX2016005785A MX2016005785A MX364310B MX 364310 B MX364310 B MX 364310B MX 2016005785 A MX2016005785 A MX 2016005785A MX 2016005785 A MX2016005785 A MX 2016005785A MX 364310 B MX364310 B MX 364310B
Authority
MX
Mexico
Prior art keywords
formulations
eye
methods
administered
immune mediated
Prior art date
Application number
MX2016005785A
Other languages
English (en)
Other versions
MX2016005785A (es
Inventor
Josefa Bernad Bernad María
A García-Sánchez Gustavo
Original Assignee
Gustavo A Garcia Sanchez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gustavo A Garcia Sanchez filed Critical Gustavo A Garcia Sanchez
Publication of MX2016005785A publication Critical patent/MX2016005785A/es
Publication of MX364310B publication Critical patent/MX364310B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a métodos y formulaciones inventivas para terapia inmunosupresora para ojo seco y otras enfermedades del ojo inmunomediadas relacionadas. Las formulaciones pueden comprender uno o más fármacos inmunomoduladores tales como rapamicina encapsulada en liposoma parenteralmente administrada y tacrolimus tópicamente administrado. Los fármacos inmunomoduladores en la presente se pueden formular y administrar para dirigirse a las causas y/o reducir los síntomas del ojo seco y/u otras enfermedades inmunomediadas relacionadas del ojo.
MX2016005785A 2013-11-05 2014-11-05 Método para preparar una formulación inmunosupresora. MX364310B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361899934P 2013-11-05 2013-11-05
PCT/IB2014/002348 WO2015068020A2 (en) 2013-11-05 2014-11-05 Immunosuppressive treatments, formulations and methods

Publications (2)

Publication Number Publication Date
MX2016005785A MX2016005785A (es) 2017-01-18
MX364310B true MX364310B (es) 2019-04-22

Family

ID=53042268

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016005785A MX364310B (es) 2013-11-05 2014-11-05 Método para preparar una formulación inmunosupresora.
MX2019004591A MX2019004591A (es) 2013-11-05 2016-05-03 Metodo para preparar una formulacion inmunosupresora.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019004591A MX2019004591A (es) 2013-11-05 2016-05-03 Metodo para preparar una formulacion inmunosupresora.

Country Status (3)

Country Link
US (1) US9801862B2 (es)
MX (2) MX364310B (es)
WO (1) WO2015068020A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170065520A1 (en) * 2015-09-09 2017-03-09 Manli International Ltd Stable liposomal formulations of rapamycin and rapamycin derivatives for treating cancer
CN108926533B (zh) * 2017-05-24 2022-03-25 江苏天士力帝益药业有限公司 一种替西罗莫司脂质体及其制备方法
CN111278401B (zh) * 2017-05-30 2023-08-15 艾克思摩尔有限公司 递送抗生素大环内酯治疗干眼综合征的组合物和方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS1685B (is) 1990-12-11 1998-02-24 Bracco International B.V. Aðferð við að búa til fitukúlur (liposomes) sem eru gæddar auknum hæfileika til að draga í sig og halda í sér aðskotaefnum
US20040198829A1 (en) 2001-04-23 2004-10-07 Sponsel William Eric Prostanoids augment ocular drug penetration
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
GB0404993D0 (en) 2004-03-05 2004-04-07 Univ Liverpool John Moores Method and apparatus for producing carrier complexes
DE602007013391D1 (de) 2006-05-19 2011-05-05 Scynexis Inc Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
CN102178649A (zh) * 2011-05-05 2011-09-14 张振华 雷帕霉素脂质体滴眼液及其制备方法

Also Published As

Publication number Publication date
US20160271115A1 (en) 2016-09-22
MX2016005785A (es) 2017-01-18
WO2015068020A3 (en) 2015-09-11
MX2019004591A (es) 2019-08-12
WO2015068020A2 (en) 2015-05-14
US9801862B2 (en) 2017-10-31

Similar Documents

Publication Publication Date Title
PH12016500953A1 (en) Tricyclic compounds as anticancer agents
MX2015010921A (es) Compuestos de carbazol utiles como inhibidores de bromodominio.
EA201592105A1 (ru) Толерогенные синтетические наноносители и терапевтические макромолекулы для снижения или усиления фармакодинамических эффектов
NZ712453A (en) Tricyclic heterocycles as bet protein inhibitors
WO2015070224A3 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
WO2015009726A3 (en) Medical uses of cd38 agonists
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
WO2015069697A3 (en) Combination therapy
IN2013MU03583A (es)
PH12015502118A1 (en) Pyridin-4-yl derivatives
EP2995304A4 (en) Composition for preventing or treating symptoms of menopause comprising soybean extract comprising coumestrol as an active ingredient
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX365403B (es) Peptidos y metodos para usarlos.
MX2016006604A (es) Derivados de piperidina con actividad multimodal contra el dolor.
MX2019004591A (es) Metodo para preparar una formulacion inmunosupresora.
MX366829B (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
EP3300482A4 (en) USE OF PRG4 FOR IMPROVING DYNAMIC SEAHARMS AND HIGHER ORDER ABERRATIONS
MX370957B (es) Compuesto de la familia de la avermectina o de la familia de la milbemicina para el tratamiento y/o la prevención de la dermatitis atópica.
MX2023003000A (es) Formulaciones de liberacion modificada de viloxacina.
MX2018015240A (es) Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica.
WO2015077334A3 (en) Therapies for left ventricular non-compaction and dilated cardiomyopathy
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.
PL402900A1 (pl) Preparat do likwidacji zakażenia sporowcami z rodzaju Nosema spp. w rodzinach pszczoły miodnej
WO2015024992A3 (en) Treatment of asthma

Legal Events

Date Code Title Description
FG Grant or registration